However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review ...

Researchers at the University of Florida have developed a new mRNA-based vaccine that, when combined with checkpoint ...

This pricing shock immediately exposed pharma’s second crisis: R&D costs that continue to climb, now between $0.8 and $2.8 ...

US Health and Human Services (HHS) Secretary Robert F Kennedy Jr has formally signed off on a recommendation to remove ...

Agentic AI refers to AI systems that add layers of reason and autonomy. They act as largely independent agents that are ...

Johnson & Johnson’s Janssen-Cilag has secured European Commission approval for a new indication of its subcutaneous ...

The Evolution Summit is designed to address the most pressing challenges and opportunities in clinical trials, with a focus ...

The 3rd Spatial Biology for Drug Development Summit is your opportunity to come together with leading biopharma experts to ...

Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from a phase 3 trial of gefurulimab, a once-weekly self-administered treatment ...

June was a slower month on the pharma agency side, but were several hires worth reporting, as well as a couple of interesting appointments on the non-profit side.

On day three of BIO 2025, editor-in-chief Jonah Comstock caught up with OS Therapies CEO Paul Romness and EVERSANA VP of ...

As usual, the one-two punch of ASCO and BIO set us a bit behind, but never fear – your June hires round-up is here at least ...